Amicus Therapeutics Inc (FOLD)

14.63
0.02 0.14
NASDAQ : Health Care
Prev Close 14.61
Open 14.64
Day Low/High 14.36 / 14.83
52 Wk Low/High 4.98 / 18.83
Volume 1.22M
Avg Volume 3.94M
Exchange NASDAQ
Shares Outstanding 164.57M
Market Cap 2.60B
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Remember, Fed News Is a Trigger for the Computers

Remember, Fed News Is a Trigger for the Computers

So I'm staying focused on stock picking.

U.S. FDA Grants Fast Track Designation For Amicus Therapeutics' Migalastat For Treatment Of Fabry Disease

U.S. FDA Grants Fast Track Designation For Amicus Therapeutics' Migalastat For Treatment Of Fabry Disease

New Drug Application Submission on Track for 4Q17

Strong Action in Individual Stocks Starts to Feel a Bit Frothy

Strong Action in Individual Stocks Starts to Feel a Bit Frothy

It's hard to predict when momentum will slow, but it could be time to take some profits when the market is as strong as this morning.

Amicus Therapeutics Announces Approval For Galafold™ (Migalastat) For Treatment Of Fabry Disease In Canada

Amicus Therapeutics Announces Approval For Galafold™ (Migalastat) For Treatment Of Fabry Disease In Canada

First Oral Precision Medicine for Fabry Disease with Broad Label for Fabry Patients with Amenable Genetic Mutations

The Flippers Are at Work and the Bears Are Hopeful

The Flippers Are at Work and the Bears Are Hopeful

Apple and its suppliers are dragging the market down.

Portola Shares Lower After Pricing Stock Offering - Biotech Movers

Portola Shares Lower After Pricing Stock Offering - Biotech Movers

The South San Francisco, Calif.-based firm said Sept. 12 it had priced its underwritten public offering of 6.35 million shares at $55 apiece.

Time to Bring Amicus Therapeutics Into the 'FOLD'

Time to Bring Amicus Therapeutics Into the 'FOLD'

Shares of this biotech look ready for further strong gains.

Teligent Shares Rise on FDA Approval for Erythromycin Topical Gel

Teligent Shares Rise on FDA Approval for Erythromycin Topical Gel

Teligent, FibroGen and Amicus Therapeutics were among the biotech stock movers in premarket trading on July 21.

This $3 Biotech Stock Is Making an 11% Move Thursday

This $3 Biotech Stock Is Making an 11% Move Thursday

In focus.

Trump's FDA: A Friendlier Biotech Sheriff

Trump's FDA: A Friendlier Biotech Sheriff

There still will be winners and losers, but the new administration's FDA is a net plus for the industry.

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Big gains could be ahead for investors willing to stick with the stock, according to one firm.

Amicus Therapeutics Submits Japanese New Drug Application For Migalastat For Fabry Disease

Represents World's Second Largest Diagnosed Global Fabry Patient Population

Biotech Movers: Akari, Array, Amicus

Biotech Movers: Akari, Array, Amicus

Akari Therapeutics, Array BioPharma and Amicus Therapeutics were among the biotech movers in premarket trading on Wednesday.

Keep Biotech Trigger Fingers Holstered

Keep Biotech Trigger Fingers Holstered

Three names show how fast biotechs can become oversold when the market acts in knee-jerk fashion.

Biotech Movers: Ionis, Alnylam, Amicus, Minerva

Biotech Movers: Ionis, Alnylam, Amicus, Minerva

Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Amicus Therapeutics and Minerva Neurosciences were among the biotech movers in premarket trading on Monday.

TheStreet Quant Rating: D- (Sell)